Vorlage:Infobox drug

Inclisiran (development codes ALN-PCSsc, ALN-60212) is an experimental drug for the treatment of elevated cholesterol, more specifically familial hypercholesterolaemia. It is a small interfering RNA that inhibits translation of the protein PCSK9.^[1][2][3] It is being developed by The Medicines Company which licensed the rights to inclisiran from Alnylam Pharmaceuticals.^[4]

In 2019 The Medicines Company announced positive results from pivotal phase III study (all primary and secondary endpoints were met with efficacy consistent with Phase I and II studies). The company anticipates regulatory submissions in the U.S. in the fourth quarter of 2019, and in Europe in the first quarter of 2020.^[5] The Medicines Company is being acquired by Novartis.^[6]

Vorlage:Reflist

• Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ: Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. In: N. Engl. J. Med. 376. Jahrgang, Nr. 15, April 2017, S. 1430–1440, doi:10.1056/NEJMoa1615758, PMID 28306389 (uu.nl [PDF]). 
• Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PL, Kastelein JJ: Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. In: N. Engl. J. Med. März 2020, doi:10.1056/NEJMoa1912387, PMID 32187462. 

• Inclisiran. In: Drug Information Portal. U.S. National Library of Medicine; abgerufen im 1. Januar 1 
• Vorlage:ClinicalTrialsGov
• Vorlage:ClinicalTrialsGov

Vorlage:Cardiovascular-drug-stub

1. ↑ Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A: A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. In: The New England Journal of Medicine. 376. Jahrgang, Nr. 1, Januar 2017, S. 41–51, doi:10.1056/NEJMoa1609243, PMID 27959715, PMC 5778873 (freier Volltext). 
2. ↑ Spreitzer H: Neue Wirkstoffe: Inclisiran. In: Österreichische Apotheker-Zeitung. Nr. 19/2017, 11. September 2017. 
3. ↑ Proposed INN: List 114. In: WHO Drug Information. 29. Jahrgang, Nr. 4. WHO, 2015, S. 531 f. (who.int [PDF]). 
4. ↑ Nick Paul Taylor: Medicines Company's PCSK9 drug hits phase 3 efficacy goals. In: FierceBiotech. 26. August 2019; abgerufen im 1. Januar 1. Fehler bei Vorlage * Parametername unbekannt (Vorlage:Cite web): "name-list-format"
5. ↑ The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran. In: The Medicines Company. Abgerufen am 29. August 2019. 
6. ↑ Novartis acquires medicines company. In: Novartis. Abgerufen am 15. Januar 2020.